Product Highlight - Pagenax

Brolucizumab is a humanised monoclonal single-chain Fv (scFv) antibody fragment.
Active ingredient: Each vial contains 27.6 mg brolucizumab in 0.23 ml solution. This provides a usable amount to deliver a single dose of 0.05 ml solution containing 6 mg of brolucizumab.
Indication: Pagenax is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Dosage & Administration: The recommended dose is 6 mg intravitreal injection every 4 weeks for first 3 doses, then individualize treatment intervals based on disease activity.
• Patient without disease activity: Treatment every 12 weeks.
• Patient with disease activity: Treatment every 8 weeks.